KAZIA THERAPEUTICS LTD(KZIA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,532 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
KZIA Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for KAZIA THERAPEUTICS LTD (KZIA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KZIA at 29.3/100 on a 32-signal composite quality model, placing it at rank #2,532 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of KZIA by reported 13-F value include Boxer Capital Management, FLPUTNAM INVESTMENT MANAGEMENT, Bleichroeder, based on the most recent SEC filings. KZIA trades on the Nasdaq exchange and files with the SEC under CIK 1075880. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KZIA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KAZIA THERAPEUTICS LTD directly from SEC EDGAR.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-98.2% YoYTotal Assets
-71.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $42.0K -98.2% | $2.3M | $0.00 | — | — | — |
| Total Assets | $6.1M -71.9% | $21.6M -23.1% | $28.1M -21.7% | $35.9M -37.1% | $57.1M +147.6% | $23.1M |
Get alerted when KZIA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for KAZIA THERAPEUTICS LTD including:
Top Institutional Holders of KZIA
Boxer Capital Management, LLC
$7.9M560,000 shFLPUTNAM INVESTMENT MANAGEMENT CO
$5.8M414,958 shBleichroeder LP
$5.6M400,000 shIkarian Capital, LLC
$5.6M396,201 shDauntless Investment Group, LLC
$5.0M354,208 shStonepine Capital Management, LLC
$4.9M345,179 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$3.5M251,700 shPoint72 Asset Management, L.P.
$2.3M200,300 shEnsign Peak Advisors, Inc
$1.6M110,778 shMILLENNIUM MANAGEMENT LLC
$1.4M101,376 sh
| Fund | Value | Shares |
|---|---|---|
| Boxer Capital Management, LLC | $7.9M | 560,000 |
| FLPUTNAM INVESTMENT MANAGEMENT CO | $5.8M | 414,958 |
| Bleichroeder LP | $5.6M | 400,000 |
| Ikarian Capital, LLC | $5.6M | 396,201 |
| Dauntless Investment Group, LLC | $5.0M | 354,208 |
| Stonepine Capital Management, LLC | $4.9M | 345,179 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.5M | 251,700 |
| Point72 Asset Management, L.P. | $2.3M | 200,300 |
| Ensign Peak Advisors, Inc | $1.6M | 110,778 |
| MILLENNIUM MANAGEMENT LLC | $1.4M | 101,376 |
More Healthcare Companies
View all Healthcare →Put KZIA on your watchlist
Track score changes the day KAZIA THERAPEUTICS LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KZIA a good stock to buy?
13F Pro's AI-powered analysis of KAZIA THERAPEUTICS LTD (KZIA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KZIA are available on the KZIA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KZIA is classified as a mid company.
Which hedge funds own KZIA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KZIA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of KAZIA THERAPEUTICS LTD's investment landscape.